Metabolic
Retatrutide
The most advanced metabolic peptide currently in late-stage clinical research. Retatrutide is a triple agonist that simultaneously activates three separate receptor pathways; GIP, GLP-1, and glucagon. Each controls a distinct aspect of how energy is regulated at a cellular level: glucose metabolism, fat storage, and energy expenditure. No other compound in its class targets all three at once, which is what makes its clinical profile so distinct from dual agonists like Tirzepatide. GLP-1 receptor activation regulates insulin secretion and slows gastric emptying. GIP receptor activation enhances insulin response and influences fat tissue directly. Glucagon receptor activation increases hepatic fat oxidation and energy expenditure, a mechanism not present in any dual agonist compound. Phase 3 trials have reported up to 24% weight reduction at 48 weeks, the highest figure recorded for any compound in this class to date. The 15mg pen suits standard research protocols. The 40mg pen is designed for extended cycles or higher-dose applications requiring less frequent administration.
€199.90 · 15mg
Available options
Product information
The most advanced metabolic peptide currently in late-stage clinical research. Retatrutide is a triple agonist that simultaneously activates three separate receptor pathways; GIP, GLP-1, and glucagon. Each controls a distinct aspect of how energy is regulated at a cellular level: glucose metabolism, fat storage, and energy expenditure. No other compound in its class targets all three at once, which is what makes its clinical profile so distinct from dual agonists like Tirzepatide. GLP-1 receptor activation regulates insulin secretion and slows gastric emptying. GIP receptor activation enhances insulin response and influences fat tissue directly. Glucagon receptor activation increases hepatic fat oxidation and energy expenditure, a mechanism not present in any dual agonist compound. Phase 3 trials have reported up to 24% weight reduction at 48 weeks, the highest figure recorded for any compound in this class to date. The 15mg pen suits standard research protocols. The 40mg pen is designed for extended cycles or higher-dose applications requiring less frequent administration.